A Study of M701 (EpCAM and CD3) in Malignant Ascites

NCT04501744 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Ascites
Cancer

Interventions

DRUG: Cohort 1 of M701
DRUG: Cohort 2 of M701
DRUG: Cohort 3 of M701
DRUG: Cohort 4 of M701
DRUG: Cohort 5 of M701
DRUG: Cohort 6 of M701
DRUG: Cohort 7 of M701

Sponsor

Wuhan YZY Biopharma Co., Ltd.